-
-
-
7 . Academic Journal
Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials
- 저자
- by Aaberg, Thomas, Jr; Abbey, Ashkan; Abdulaeva, Elmira; Abengoechea, Santiago; Abraham, Prema, et al.
- 소스
- In The Lancet 19-25 February 2022 399(10326):741-755
-
7 . Periodical
Intravitreal aflibercept 8 mg in diabetic macular oedema (PHOTON): 48-week results from a randomised, double-masked, non-inferiority, phase 2/3 trial
- 저자
- by Brown, David M; Boyer, David S; Do, Diana V; Wykoff, Charles C; Sakamoto, Taiji, et al.
- 소스
- The Lancet; March 2024, Vol. 403 Issue: 10432 p1153-1163, 11p
-
7 . Periodical
Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials
- 저자
- by Wykoff, Charles C; Abreu, Francis; Adamis, Anthony P; Basu, Karen; Eichenbaum, David A, et al.
- 소스
- The Lancet; February 2022, Vol. 399 Issue: 10326 p741-755, 15p